To further investigate the effect of SGLT2 inhibition on OSA incidence, we performed a post hoc analysis of VERTIS CV, a double-blind, placebo-controlled trial of the efficacy and safety of the SGLT2i ertugliflozin in patients with T2D and ASCVD. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.